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Highlights 
 Cancer stem cells (CSCs) provide a cellular origin for prostate cancer. 
 
 The distinctive phenotype of CSCs overlaps that of normal prostate stem cells. 
 
 Inflammation has a synergistic role in prostate tumourigenesis. 
 
 Pre-malignancies support pre-tumour development in the prostate. 
 
 Genetic and epigenetic aberrations create divergent molecular subtypes of cancer.  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
Abstract 
Prostate cancer is the most commonly diagnosed male malignancy.  Despite compelling 
epidemiology, there are no definitive aetiological clues linking development to frequency.  
Pre-malignancies such as proliferative inflammatory atrophy (PIA) and prostatic intraepithelial 
neoplasia (PIN) yield insights into the initiating events of prostate cancer, as they supply a 
background “field” for further transformation. An inflammatory aetiology, linked to recurrent 
prostatitis, and heterologous signalling from reactive stroma and infiltrating immune cells may result 
in cytokine addiction of cancer cells, including a tumour-initiating population also known as cancer 
stem cells (CSCs). In prostate tumours, the background mutational rate is rarely exceeded, but 
genetic change via profound sporadic chromosomal rearrangements results in copy number 
variations and aberrant gene expression. 
In cancer, dysfunctional differentiation is imposed upon the normal epithelial lineage, with 
disruption/disappearance of the basement membrane, loss of the contiguous basal cell layer and 
expansion of the luminal population. An initiating role for androgen receptor (AR) is attractive, due 
to the luminal phenotype of the tumours, but alternatively a pool of CSCs, which express little or no 
AR, has also been demonstrated. Indolent and aggressive tumours may also arise from different 
stem or progenitor cells.  
Castrate resistant prostate cancer (CRPC) remains the inevitable final stage of disease following 
treatment. Time-limited effectiveness of second-generation anti-androgens, and the appearance of 
an AR- neuroendocrine phenotype imply that metastatic disease is reliant upon the plasticity of the 
CSC population, and indeed CSC gene expression profiles are most closely related to those identified 
in CRPCs. 
Introduction 
Prostate cancer is, apart from hereditary cases, a disease of old age with a peak incidence in men of ~70 years. 
(1) No evident epidemiology supports the high frequency of this malignancy, compared to chemical 
carcinogenesis such as smoking for lung cancers. (2) The heterogeneity of the gland itself has imposed many 
barriers in the search for an aetiological origin of prostate cancer. (3) 
The human prostate is a glandular organ situated inferior to the bladder, Figure 1A. composed of epithelial 
acini arranged in a fibromuscular stromal network. The epithelia are highly organised into a contiguous basal 
layer containing 3 major cell sub-types; stem, transit amplifying (TA) and committed basal (CB) cells, which 
account for ~40% of total epithelial cell numbers, and a layer of columnar secretory luminal cells that make up 
the rest of the epithelium. Figure 1B. (3,4) 
 
 
 
 
Figure 1. Human prostate anatomy and epithelial cell constitution 
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A. The prostate is located beneath the bladder and is composed of 3 distinct zones; the central zone (CZ) that 
contains the ductal tube from the seminal vesicle to where it meets the descending urethra, the peripheral zone 
(PZ) which is situated at the posterior of the gland and is the region from where the vast majority of PIN and 
cancer arises, and the transitional zone (TZ) that is directly below the bladder and surrounds the transitional 
urethra. BPH occurs in this region of the prostate. 
B. Diagrammatic representation of a normal prostatic acinus; the epithelial bilayer of basal and luminal cells, 
surrounded by fibromuscular stroma. The relative content of different epithelial cells in the normal prostate are 
summarised graphically; luminal (60%), basal (40%) with the stem cells constituting ~1% of total epithelia. 
C. Cellular composition of a cancerous acinus. Cancer is characterised by luminal hyperproliferation, loss of the basal 
layer, breakdown of basement membrane, immune cell infiltration and stromal reactivity. Cancer skews the 
epithelial cell percentages; the luminal cells make up >99% of tumours, basal CSCs are estimated to constitute 
<0.1% of tumour epithelial cells. 
It is likely that tissue stem cells source the prostatic epithelial lineage; asymmetric division produces a non-
stem daughter TA cell that bulks the basal layer through rapid mitosis and differentiation into CB cells. Figure 
2A. In humans, the end-stage basal cell then develops into a terminally differentiated luminal cell, and moves 
towards the acinar lumen. (5–7) In prostate cancer, and indeed in the disease’s postulated pre-malignancies, 
there is disruption of the epithelial lineage, followed by a skewing of cell population numbers. (8) Prostate 
carcinomas present with a dominant luminal phenotype, disruption or absence of the basement membrane, 
(9,10) and contain reactive stroma that aid tumour growth through heterotypic signalling. Figure 1C. (11–15) 
In the search for a cell-of-origin that can establish the tumour, it is logical to suppose that the offender must 
be of a luminal phenotype. However a basal cell origin provides a less obvious but increasingly supported 
alternative in man. (16) 
This review is centred upon discerning the origins of human prostate cancer and is divided into three parts. 
The first discusses the cellular origins of prostate cancer, the second; prostate cancer’s inflammatory aetiology, 
and the third – the pre-malignancies of the disease alongside the specific molecular defects of the cancer.  
Are all Tumour Cells Equal? 
The prostate is composed of variable cell populations; within an organised epithelial lineage, a fibro-muscular 
stromal network, the endothelial vasculature and a variety of immune cells. Figure 1B. Most tumours 
represent a tissue established by a dysfunctional differentiation program based upon a similar cellular 
hierarchy. (17,18) Currently there are two hypotheses that account for the heterogeneity evident in cancers; 
malignancies that have probably arisen from multiple genetic and epigenetic changes in a single cell, and the 
existence of a cancerous progenitor cell which sources a dysregulated differentiation program to form the 
tumour. 
Clonal Evolution or Stochastic Model 
In this model, a definitive transformational event first affects an oncogenic or tumour suppressing gene, and a 
subsequent mitosis produces another cell that has equal tumour propagating potential. Heterogeneity is 
generated by further step-wise mutation in the progeny of the founder cell. Sequential accumulation of other 
genetic lesions in this field creates variant clones that can be traced to the founder event. (19–21) Figure 2C. 
This has been modelled through transformation of cells by introduction or removal of genes recurrently 
identified to be altered in human cancer across multiple cell types. Around 140 so called tumour suppressor 
and oncogenes have now been identified to drive cancers across different tissue types. (22) 
Further evidence for a sequential model comes from the observation of field cancerisation (FC). As first 
described in oral cancers,(23) FC explains the spatial proximity of multi-focal primary tumours, where an area 
of tissue represents a “field” that has a predisposition to carcinogenesis. Each individual cell in the field thus 
has an enhanced propensity to undergo transformational change and to establish sub-fields in which further 
mutagenesis can occur.(24) There is increasing evidence for FC in prostate cancer. (reviewed in 25) For 
example, by determination of methylation ratios of APC and RARβ2 across adjacent benign and malignant 
tissue, an underlying epigenetic field could be detected. (26) More recently, deep-sequencing of three prostate 
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cancers identified a surprisingly high number of somatic mutations in “normal” epithelia, which in the 
prostate, where a low background mutation rate has been postulated, is totally unexpected. The authors 
attributed this elevated base-level of mutation to a background field effect that sourced the multi-focal 
distribution of the tumours that they were investigating. (27) Another experimental approach to FC, is the ex 
vivo sequential mutagenesis of normal human prostate epithelial cells. Goldstein & Witte et al. introduced the 
driver genes ERG and AKT, by lentivirus, into basal cells that were then able to constitute lesions which 
resembled prostatic intraepithelial neoplasia (PIN). Further addition of androgen receptor (AR) caused 
formation of adenocarcinomas that, in some cases, lost the basal layer and had concomitant expansion of an 
AR
+
 luminal population. This observation supports the premise that histological character of the cancer upon 
presentation is not congruent with the state of the malignancy at its origin. (28) 
Cancer Stem Cell Model 
The cancer stem cell (CSC) hypothesis states that not all of the cells in the tumour are able to reconstitute the 
tumour mass after dissociation. There exists a distinct and, in most cases, minor sub-population of cells that is 
responsible for tumour initiation, renewal and relapse post-treatment, and mirror normal proliferative tissue 
dependence on a somatic stem cell population. This CSC pool lies at the base of an aberrant differentiation 
lineage, which results in the cellular variance of prostate and many other major human tumours. (29–32) 
Figure 2D. 
However the stochastic and CSC models are definitely not mutually exclusive. Figure 2D. It is entirely plausible 
that the CSCs can establish early pre-tumour development and also allow for relapse, whereas in late-stage or 
aggressive disease it is more likely that a CSC-derived dominant clone with an enhanced proliferative and 
invasive capability will drive the cancer. The CSC pool can also maintain genetic heterogeneity that will derive 
successful clones. (33) 
The CSC hypothesis is compatible with an intermediate stage in carcinogenesis; pre-tumour development, 
where all the driver oncogenic mutations and genetic aberrations accumulate in the stem or progenitor cell, 
prior to actual tumourigenesis and the phenotypic emergence of visible cancer. Necessarily, this would occur 
over a long period of time. Adult stem cells are the only cell type in a tissue that aren’t, under normal 
conditions, depleted through either differentiation, development or cell death. The slow turnover and relative 
quiescence of the stem cell also explains the slow progression and late presentation of prostate cancer. (18,34) 
A recent publication from Tomasetti & Vogelstein (35) commented on the positive correlation between 
number of stem cell divisions and the incidence of cancer in tissues. However, misappropriation of the term 
“bad luck”, underestimation of environmental factors, the use of data from only the United States and absence 
of major cancer types including; breast, stomach, cervix and prostate, in analysis has attracted subsequent 
criticism. (36–42) Carcinogenesis is a far too convoluted process to attribute random mutation in stem cell 
divisions as the major and unavoidable risk factor in disease development. The high frequency of cancer 
incidence among the population and the number of mutations seen in solid tumours, without the acquisition 
of a mutator phenotype through defective mismatch repair or genomic instability, is not explicable in a 
stochastic multi-hit model using a baseline mutation rate of 10
-7
-10
-9
 (34,43–45) and is therefore suggestive of 
a Darwinian selection through micro-evolutionary processes. (34,46,47) Selection of mutations through 
conferred proliferative or survival phenotypic advantages, in the setting of field cancerisation, would create a 
niche microenvironment where successive mutations are accrued in a single cell. In a recent and thought 
provoking study, Ling et al. analysed ~300 samples from a single hepatocellular carcinoma.(48) They found 
unexpected genetic diversity amongst clonal populations, with mathematical modelling suggesting a Non-
Darwinian mode of selection in the solid tumour, and an extremely high mutational load. Relation of genetic 
heterogeneity to the definitive functional non-equivalence of cells, especially on the drift of low frequency 
passive mutations, alongside an inability to predict exact selection pressures within the tumour mass itself 
limits analysis. A further study conducted by Williams et al., using mathematical modelling on the evolution of 
cancer genome sequences, identified presence of driving mutations in the “first” cancer cell and that the noise 
of passenger mutations creates observed intratumoral heterogeneity whilst separate lineages evolve in a 
neutral manner and accumulate passive driver events that can, later, confer treatment resistance.(49) Thus 
supporting a dominant role of pre-tumour development over subsequent clonal evolution within cancers.   
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Figure 2. The Human Prostatic epithelial hierarchy, stem cell division and Stochastic/CSC models of cancer. 
A. Simplified prostate epithelial lineage hierarchy. From a self-renewing stem cell, luminal cells are formed by the 
step-wise differentiation of the cell through transit amplifying and committed basal states. 
B. Outcomes of stem cell division. 95% of division occurs asymmetrically, maintaining the stem cell pool and the 
epithelial cell lineage. The remaining 5% of divisions are symmetrical, leading to either the expansion or the 
extinction of the stem cell population.  
C. Stochastic model of tumour heterogeneity. In C1, mutation x1 transforms a TA cell that then produces a field of 
more differentiated CB cells. The second mutation is incurred in a CB cell that can only propagate this in the CB 
and luminal cell populations. The mutations are assumed to confer an ability of self-renewal so that the cells 
aren’t lost by progression through the epithelial cell lineage, thus every cancer cell has roughly equal 
tumourigenic potential in this model of clonal evolution from a field of cancerisation. C2 – A schematic of a tumour 
representing the epithelial lineage of the C1 stochastic model. 
D. Cancer Stem Cell model. The postulate for the hypothesis; is that only the CSC has the potential to generate a 
tumour. Mutation x1 in the SC creates a tumour lineage derived from this stem cell. Mutation x2 represents a 
merging of the CSC and stochastic models, as the two are not mutually exclusive. Here, after symmetrical division 
of the CSC in niche succession, a secondary mutation occurs in the CSC, resulting in a variant tumour hierarchy, 
that is genomically/epigenetically different from the first CSC lineage. D2 – A schematic of a tumour representing 
the lineage of the D1 CSC model. 
Niche Independence as a Driver Mutation 
Normal somatic and CSCs in vivo are maintained by, and indeed maintain, a protective niche within tissues. In 
light of this, it is likely that a key driver mutation class in cancer will be to confer niche independence or the 
ability to generate a new niche to a CSC. The best evidence for a CSC niche comes from glioblastoma, in which 
CSCs are maintained by a hypoxic micro-environment, (50) yet can also trigger angiogenesis through a CSC 
fraction that acts as an endothelial progenitor. (51,52) In the prostate, this encapsulating micro-environment 
of cellular contacts and a potent cocktail of growth factors is most likely situated on the basement membrane, 
due to high stem cell expression of collagen-binding α2β1. Here, the stem cell is exposed to heterotypic 
interaction with the underlying stromal compartment. (15,53,54) Extrinsic factors supplied by this niche, along 
with intracellular molecules contained within progenitors themselves, will affect key developmental decisions 
such as symmetric or asymmetric division. Figure 2B. (55,56) The niche for prostate epithelial stem cells 
requires further research, as this may establish a direct difference that can be attributed to a malignant stem 
cell phenotype and maintenance. (57) Interestingly, niche similarity or mimicry may explain the bone tropism 
displayed by metastatic prostate cancer. (58) 
How do Driver Mutations occur? 
Accumulation of driver mutations by fixation and passenger mutations by drift can be modelled in selective 
sweeps of niche succession by an individual stem cell. Niche succession is thought to be a cyclic process that 
occurs once every 8.2 years (median) in the colon, and presumably takes place at much slower rates in low 
turnover tissues such as the prostate. (34,59) Advantageous mutations, at least in initial pre-tumour 
development would confer an enhanced ability of the stem cell to remain niche-bound and may also promote 
expansive symmetric division. Stem cell biology is also significantly different from that of a differentiated cell, 
with cell fate structured around different pathways. On current evidence, “successful” CSCs manage to 
maintain their stemness pathways such as Notch, Wnt and Hedgehog intact or in a hyper-activated state, as 
molecular inhibitors targeting these networks abrogate CSC effectivity. (60) There is also a strong possibility 
that mutations deleterious to cells of a more differentiated phenotype can be tolerated, or may in fact remain 
silent/have reduced penetrance. This is observed in pediatric tumours, in the tumour progenitor population. 
(22,61) A situation can therefore exist in which somatic stem cells, from birth, act as a potential neoplastic field 
for accumulative genetic change over an individual’s life-time. In prostate, the initiation events most likely 
occur during the two waves of prostatic development and expansion; neonatally and at puberty. Such neonatal 
expansion is driven (in AR
-
 cells) by growth factors supplied through the stromal micro-environment. (3) 
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Direct transformation of somatic stem cells presents a compelling case for establishment of a founder event in 
the stem cell, rather than a near-progenitor as observed in colorectal crypt cells. Here, only transformation of a 
stem cell allowed formation of an adenocarcinoma, whereas malignant initiating TA cells had limited self-
renewal and thus could only form abortive cancers. (29) The colon constitutes an excellent model for studying 
direct transformation as so much is known of crypt cells, niche succession and mitotic turnover. (62) 
Transformation of a stem cell in the colon was the most plausible explanation for initiation of colorectal 
cancer, as mutations in more differentiated cells would have no time to accumulate due to the rapid turnover 
of cells in the intestine. Transformation of a non-stem cell would require mutation alongside an additional co-
incident event such as micro-environmental change or an inflammatory stimulus, which is improbable yet 
possible. (63) In the prostate, an organ which has a much slower cell turnover, the chances of non-stem 
originated cancer will be increased in accord with this reasoning, yet a stem cell event would still remain the 
most logical origin for tumour initiation. 
The Evidence for Cancer Stem Cells 
CSCs were postulated as a cell-pool long before the ability to fractionate individual cellular populations. (17) 
When technology was able to isolate living cells with specific cell surface phenotypes, the first direct evidence 
of a clonogenic cell fraction in cancers came from acute myeloid leukaemia (64). Here leukaemic progenitor 
cells were selected using the immunophenotype of haematopoietic stem cells (HSCs); CD34
+
CD38
-
, and were 
able to not only reconstitute the leukaemic blast hierarchy but also to possess extensive self-renewal 
capabilities. CSCs have now been derived in many cancers using commonly conserved immunophenotypic 
markers. (30) Table 1 
  Table 1 –immunophenotypes of Human Cancer Stem Cells 
Isaacs and Coffey were first to postulate the existence of an aberrant stem cell population in the prostate. (78) 
This prediction was realised when Collins et al. enriched a tumour initiating cell-type from human prostate 
cancers. (32) These basal stem cells, classified through expression of canonical markers including p63, CK5 and 
CK14, and a lack of AR, prostate specific antigen (PSA) and PAP luminal identifiers, (77, reviewed in 16) can be 
fractionated from radical prostatectomy biopsy cores by selection of a CD44
+
 α2β1
hi
 CD133
+
 phenotype. The 
fact that these markers also isolate stem cells of the non-malignant prostate adds further weight to a CSC 
origin of prostate cancer. (53,80) This cell class constitutes fewer than 0.1% of tumour cells and has markedly 
enhanced invasive potential and self-renewal over normal tissue stem cells. (32) We have also demonstrated 
that hallmarks of canonical chromoplexy such as the TMPRSS2-ERG fusion (81,82) and PTEN deletion (Butler et 
al. manuscript in preparation) exist in this cell-pool, although further work to fully characterise the extent of 
genomic aberration is required. Classical stem cell markers such as Bmi-1 and nanog have also been identified 
in prostate epithelial and cancer stem cells. (83–85) Recently, basal cells have demonstrated a significantly 
enhanced organoid generating ability from single cells over those of a luminal phenotype, further evidencing a 
basal cell of origin. (86) 
Surface marker classification is by no means a definitive determination of the CSC cadre of the prostate. Inter-
CSC variance has been known to exist for decades. (87) If we view the tumour like its tissue counterpart, (88) 
aberrant acini will have separate stem cells and thus CSC niches. In addition, the “cancer” phenotype can be 
reached by multiple genetic and epigenetic routes, which will be superimposed on a more consistent stem-like 
phenotype. Both intra- and inter-niche heterogeneity will contribute to the plethora of sub-clonal properties of 
CSCs in constitution of the disease itself, (89–93) metastases, (94,95) dormancy (96) and therapy resistance. 
(30,97) One truly interesting prospect is that indolent and aggressive cancers may have non-convergent roots 
in distinct CSC sub-types, a topic of further intrigue if it is found that Gleason grades are divergent rather than 
progressive.  
Gleason Grading of Prostate Cancer 
In prostate cancer there are currently no definitive markers that can differentiate indolent and malignant 
varieties of tumour better than the classic histopathological Gleason grading system (98) which distinguishes 
malignancy on comparative tissue architecture. Figure 3A. (10,99) However, it is still not confirmed whether 
Gleason grade of tumour tissue is transitional; increasing over time as disease progresses, or clonal; with 
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divergent cells of origin for Gleason 3, 4 and 5 patterns. Both transitional and clonal models have supporting 
evidence and may not necessarily be mutually exclusive. Temporally repeated biopsy of the disease in the 
same prostate is theoretically the best way to conduct this research. However this strategy will be restricted by 
significant needle biopsy sampling errors, prostate tissue heterogeneity, and the frequently multifocal nature 
of primary prostate cancer. (99–101)  
In support of a transitional model; Gleason grade correlates positively with age at detection i.e. older men are 
diagnosed with more aggressive cancers. (101) This could however be countered by the fact that higher 
Gleason grade cells may be relatively undetectable earlier in the natural history of disease and may initiate 
growth at a later point. Laser capture micro-dissection (LCM) of adjacent G3 and G4 tissues, followed by 
genome sequencing of the lesions identified sharing of common breakpoints and early genetic events such as 
chromothripsis and TMPRSS2-ERG fusions, between the two tissue grades. Even in samples that, at first, 
seemed genomically disparate, it was shown that a small population of the Gleason 3 cells had “stemmed” the 
Gleason 4 lineage through sufficient sequencing depth, providing molecular evidence of a transition. Figure 3C. 
(102) Equally, there could still be a common progenitor clone for each lesion.  
Figure 3. Gleason grading and progression hypotheses 
A. Gleason patterns adapted from the 2010 ISUP consensus on pathology. Cumulative Gleason grades are given for 
the 2 dominant patterns in cancerous tissue, meaning a score of 2-10 can be awarded. 
 
B. Clonal model of Gleason progression. Here Gleason 3 and 4 tissues have distinct progenitors that stem respective 
indolent and aggressive cancers. 
 
C. Transitional model of Gleason progression. A Gleason 3 cell accumulates further epigenetic/mutational changes 
required for the cell to progress and form a more advanced Gleason pattern. 
 
Indication of separate clonal events propagating Gleason 3 and 4 tissues is seen in both population and 
expressional studies. PSA testing has permitted detection of prostate cancer earlier in the individual tumours’ 
natural history, than before implementation of the biomarker.  Thus earlier detection of cancers should reduce 
the absolute numbers of patients diagnosed with high Gleason cancer, as lower grade cancers haven’t had 
time to progress to the more malignant phenotype. However a large population study found that, at diagnosis, 
the incidence of >G7 cancers in the pre and post-PSA testing eras had remained at the same level. (101) The 
presence of Gleason pattern 4 in tumours significantly reduces progression free survival.  Gleason 3+3 cancers 
only rarely progress to lethal disease (103,104) yet the presence of a tertiary component of Gleason 4 is 
predictive of biochemical relapse of the cancer, (105) suggesting that a cell detached from the Gleason 3 tissue 
is responsible for malignant progression. Figure 3B. 
Gleason 4 and 5 cancers are reported to be indistinguishable in their expression signatures, possibly due to 
heterogeneity, whereas there is a clear separation of Gleason 3 and 4 transcriptomes. (106) An 86 gene 
signature was able to divide 81% of cancers on this molecular correlate and identified genes such as 
monoamine oxidase A that are upregulated in Gleason 4 pattern lesions over those of Gleason 3 status. We 
also showed that Gleason 6 (3+3) cancers were distinguishable in their expression profiles from Gleason 7 
cancers. Interestingly when these Gleason 6 cancers were included in total analysis, the distinction of 
malignancy (cancer-benign) and differentiation state seen with >G7 cancers was lost. (81) However such 
robust expression signatures for separate Gleason grades weren’t identified in a similar micro-array based 
investigation, one possible explanation of this disparity would be a dominant luminal cell expression signature 
masking the expression differences observed by our study. (107) 
While doubt still remains about the nature of prostate cancer progression and lineage involvement from a cell 
of origin in the disease, more research into the molecular evidence of progression is required. Studies that 
account for disease heterogeneity by cellular fractionation, LCM or deep sequencing will hold the true 
discovery potential in future prostate cancer research. The more benign nature of lower Gleason grade 
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tumours (108) is now reflected in a histopathological consensus classification which still bears Donald 
Gleason’s name. (109) 
Quiescence and Stem Cell Initiation of Cancers 
CSCs don’t necessarily have to gain an enhanced proliferative potential to fuel a “successful” cancer. 
Maintenance of a quiescent state is advantageous, as it removes the threats of chemotherapy and the “fixing” 
of deleterious mutations from radiotherapy, as seen in therapy-resistant normal adult HSCs. (110) 
The loss or breaking of adult stem cell dormancy transitions stem cells to an “activated” state of increased 
mitotic potential. (111) Loss of a differentiated cellular hierarchy through bleeding (112) or chemotherapy 
(113) primes dormant HSCs into an activated state, allowing for re-constitution of the haematopoietic lineage. 
These cells then return to dormancy in their niche. (114) Somatic stem cell niche maintenance seems to be 
extremely important in the retention of a quiescent state. (113,115) Whether this model can translate 
effectively to the epithelial stem cells of the prostate is still to be determined. 
CSC-initiated relapse involves an extended period of quiescence; a dormant subpopulation of CSC may direct 
this observed pause before relapse of metastatic disease. (30,116) Possible treatment scenarios for this 
population include; maintenance of stem cell dormancy so that they can’t direct regrowth, or priming the cells 
into a cycling mitotic/more differentiated state then following up with conventional chemotherapeutical 
killing. (96,113) Differentiation therapy is an intriguing possibility that has been discussed previously in 
prostate cancer (43), however the main challenge in establishing this treatment is to ensure that the induced 
development is selective for CSCs, while leaving normal adult stem cell quiescence uninterrupted. Outcome in 
non-targeted treatments of this sort would be deleterious to gland integrity. 
Asymmetric division facilitates the self-renewal of the stem cell population. It has been hypothesised that this 
process also confers mutational protection on the stem cell pool. The immortal strand hypothesis was 
proposed by Cairns in 1975 (117) – as the mutational accumulation in epithelia is lower than expected 
background rates, stem cells may non-randomly retain their template chromosomes or strands so that 
mutations incurred in the replication process are passed on to their non-stem daughter. (118,119) This makes 
the assumption that stem cells must minimise recombinatory DNA repair and limit mitotic sister chromatid 
exchange to keep the immortal strand “pure” and, counterintuitively, HSCs have been found to have deficient 
DNA repair. (120) Selective strand segregation has been observed in embryonic fibroblasts, (121) mouse 
intestinal stem cells (122) and skeletal muscle stem cells. (123) More recent evidence however has argued 
against the hypothesis. HSCs (124) and mouse intestinal stem cells (125) have been shown to randomly 
separate their template chromosomes through temporal dilution of variant DNA-labels and a recent meta-
analysis of sequencing data has also provided an argument against existence of an immortal strand. (126) By 
modelling expected mutational accumulation in healthy stem cells using the assumption of an immortal strand 
system, it was shown that cancers of the head and neck, blood and colon had a greater than hypothesised 
mutational load – suggesting random chromosomal segregation into daughter cells. The limitations of 
comparing modelled normal stem cells and cancer sequencing data must be noted, as this doesn’t account for 
particular mutations in the cancer that could support a mutator phenotype. Equally, a hallmark of CSCs in pre-
tumour development may be the disruption of regulatory pathways that govern strand segregation, proposed 
to be centred upon p53, (127) to create a setting for cumulative mutations in the tumour progenitors. 
Mouse Models of Prostate Cancer 
The favoured animal model for human prostate disease is the mouse. Studies using mice have permitted the 
application of xenograft experimentation and genetic engineering. (reviewed in 10,126) Xenografting of cell 
lines and primary human cells has yielded significant information on the molecular mechanisms of prostate 
cancer yet also presents new challenges, due to the heterologous mouse tissue environment and the lack of an 
endogenous immune system in the mice. (10) In terms of CSC dynamics, the niche in mouse tissue will not re-
capitulate that of the cell in culture or indeed in the human prostate. Hypothetically the xenografting of 
tumour cells may select for a variant dominant CSC that supports tumour initiation in the mouse. The stromal 
compartment of the prostate is extremely important in the development of cancer, and addition of human 
stromal cell lines into xenografting studies enhances tumourigenicity of the cancer cells. (129,130) 
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Current evidence can support both a basal (131,132) and luminal (133,134) CSC model of disease in the mouse 
prostate (135) via multipotent, bipotent (136) and unipotent (137) stem cells that also differ in symmetry of 
their division to produce cells with inequivalent aggressiveness.(138) However human cancers provide more 
proof for a basal CSC (32,83,139–141) despite some evidence for luminal progenitors. (142) 
Although studies using transgenic mice have shed light on many human diseases, there are many anatomical 
differences between the mouse and human prostates. Firstly, the mouse prostate doesn’t spontaneously 
develop neoplasia and instead atrophies with increasing age,(143) a situation in stark contrast to benign 
prostatic hyperplasia (BPH) and cancer development in the human organ. Basic anatomy is also divergent; the 
mouse prostate is composed of three lobes around the urethra whereas the human prostate is alobular and 
envelopes the upper portion of the urethra. (144) Glandular structure between the two species also differs. 
Human acini are composed of two distinct epithelial layers compared to the single mixed layer of epithelial 
cells found in the mouse prostate. (3) As prostate cancer doesn’t naturally develop in the mouse, any parallels 
drawn between the two species have to be carefully considered. The act of forcing a non-naturally occurring 
scenario on a system will inherently introduce artefacts that are open to misinterpretation. 
Epigenetic Aetiology of Cancer 
Over recent years it has been observed that the epigenome of cancer cells is perturbed to the same extent as 
their genomes. (145) Epigenetics, the marking of DNA (by repressive methylation) or histones (primarily 
through activating acetylation and both activating and repressive methylations), allows for plastic and flexible 
control of gene expression. (146) This is entirely in keeping with current hypotheses of gene regulation in adult 
stem cells, which have to simultaneously remain in a dedifferentiated state yet retain the potential to resolve 
gene-sets and enter distinct lineages of differentiation. (55,147,148) Meta-regulation of the epigenetic control 
of gene expression can become dysregulated in tumours by over-expression, mutation or loss of chromatin 
modifying enzymes, a common occurrence in prostate cancers. (107,149,150) 
Early stem cell histone marks have been shown to predict gene downregulation, followed by stabilising DNA 
methylation in many cancers (151–153) including that of the prostate. (154) Initial bivalent histone 
modifications at tumour suppressing loci can thus predict the epigenetic silencing of the gene in malignancy. 
Epigenetic plasticity is also employed in epithelial to mesenchymal transition (EMT) – a metastatic signature 
dominant in the CSCs of the prostate. (79,81) Tumour cells thus can use epigenetics to retain more plastic and 
adaptable de-differentiated states, without relying on inflexible and fixed mutations to drive carcinogenesis. 
These epigenetic mechanisms also have the propensity to silence mutant alleles until a time when they 
become tolerable in the cell i.e. when quality control pathways have been dysregulated. Oncogene activation 
has been previously reported through loss of promoter DNA methylation (155) and repressive histone marks. 
(156) Indeed promoter hypomethylation in prostate cancer has been reported to facilitate aberrant expression 
of Wnt5a, production of which correlates with disease malignancy (157) and the utilisation of the Wnt 
pathway by circulating tumour cells (CTCs) in castrate resistant disease. (158) 
Heterogeneity of Gene Expression and Random Monoallelic Expression in Prostate Cancer 
Prostate cancer presumably develops due to genetic and epigenetic insults accumulated by a single cell, which 
then proceeds to generate an extensively heterogeneous tumour. Accounting for cellular variance in disease 
and understanding the mechanisms of tumour cell diversification is critical to all investigations of prostate 
cancer development. Most discussions of tumour heterogeneity centre upon genetic aberration and 
mutational differences that separate distinct sub-clones. However there is also the factor of expression 
heterogeneity. In the situation of common heterozygous mutation, is selective expression of the mutant 
transcript over that of the wild-type allele critical for tumour development? This impacts upon cancer 
therapies, as it can generate unimaginable variance within a tumour, through production of stochastic intra-
clonal heterogeneity. (159,160) In turn, generation of vast heterogeneity significantly raises the potential of 
the selection of one cell by favourable adaptation to a micro-environmental change, or in response to a new 
treatment regimen. Thus there are two primary variables to take account of when assessing expressional 
variance amongst cells;   
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The first is the level of mRNA transcript – in tumours; excessive oncogenic mRNA or loss of transcription at a 
tumour suppressing locus will inevitably affect cellular contributions to the cancer. Recent single-cell studies 
have indicated that normal cellular mRNA expression varies greatly, even in clonal cells (161) with the same 
also holding true in cancer cells. (162–165) 
The second factor is that different cells will have variant allelic preferences amongst gene sets. The 
phenomenon of random monoallelic expression (RME) is distinct from that established by aberrant promoter 
methylation, or locus deletion detected in cancers. An allele has a stochastic activation upon development 
from a stem cell, meaning that the gene can be either; biallelically, maternal monoallelically, paternal 
monoallellically expressed or isn’t expressed at all. The allelic “choice” is mitotically stable in the non-stem 
daughter upon asymmetric division and adhered to throughout mitosis and differentiation. Figure 4B. 
(166,167) Fixed monoallelic expression in TA cells, and more differentiated progeny, will thus populate the 
tissue, creating an ever shifting cellular expressional mosaic based on initial allelic “choice” established from 
the CSC. Figure 4C. Indeed mosaic expression has been shown for key driver genes amongst single cells in 
glioblastoma. (164) RME was initially observed in cell culture (168,169) and hypotheses that it exists as an 
artefact of this artificial environment have now been dispelled by multiple in vivo studies. (166,170–172) 
The regulation of allelic choice, in the majority of RME genes (166) is not controlled by correlative methylation 
of promoter CpG islands (82,173,174) as originally thought. Strand-specific methylation could account for 
switching in active alleles at mitosis, however recent higher resolution promoter analysis implies that RME is 
defined by an asymmetric chromatin signature in which the gene body histones of the active allele are tri-
methylated at H3K36 and the silenced allele are trimethylated at H3K27. (170) This fingerprint has been shown 
to be predictive of RME status and is conserved in orthologous mouse genes (175) suggesting that regulation 
of allelic expression is hardwired in our DNA, due to the evolutionary distance between mice and humans. 
Interestingly many of the genes found included in the RME chromatin structure were also bivalent in ESCs. 
(170) Bivalent chromatin is formed by dual deposition of respective activating and repressive modified 
histones H3K4me3 and H3K27me3 at promoter regions, allowing for rapid activation of genes upon stem cell 
differentiation. (176) Resolution of the somatic stem cell bivalent marks into those seen in RME is an 
important hypothesis. (170,177) Bivalent genes, like RME gene-sets, are lineage specific and are involved in 
cancers of various tissues (152,153,178–182) including the prostate. (154) Figure 4A. 
Figure 4. Epigenetics and Tissue Patterns of Random Monoallelic Expression 
A. Histone and DNA methylations involved in the maintenance of bivalent and randomly monoallelically expressed 
genes. Green represents transcriptionally activating marks while the red denotes marks involved in gene 
repression. The stars indicate that the methyltransferase/demethylase has been shown to be dysregulated in 
prostate cancer. 
B. Generation of RME from bivalent stem cell genes. The “choice” of allelic activation is made at each allele 
independently, allowing production of variant TA populations. The number of genes affected by RME and the 
stochastic resolution of allelic expression upon development allows for heterogeneity of expression to develop 
more extensively across tissues. 
C. Tissue mosaicism of allelic expression. The stability of RME patterns throughout mitosis and differentiation 
reasons that tissues would form mosaics, based upon allelic expression that originates from the SC niche and 
spans both basal and luminal epithelial layers.  
Current evidence of RME affecting cancer initiation is sparse, as most studies have focused on development. 
The first reports of tumourigenic RME occurred in chronic lymphocytic leukaemia patients that had 
haploinsufficiency of DAPK1, (183) where the RME status of the gene was confirmed in peripheral 
mononuclear blood cells.(169) TMPRSS2-ERG, the commonest genetic abnormality in prostate cancer, 
(149,184) is regulated by RME pre-fusion. Upon recombination with the ERG gene, the fused allele becomes 
dominant and is selectively monoallelically expressed in the CSC. Suppression of the unfused TMPRSS2 allele is 
later relaxed in development, with randomisation of allelic expression outside of the stem cell compartment. 
This perturbation of RME in cancer, generates epigenetic plasticity of the propagating cell and results in 
expression heterogeneity. (82) 
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RME in cancer has the potential to both silence tumour suppressing loci and to allow selective expression of 
oncogenic alleles. Conversely, it is probable that tumourigenic alleles are silenced in this manner during pre-
tumour development and later re-activated. This can lead to situations of variable penetrance and may 
account for some instances of haploinsufficiency. For a greater insight, single-cell RNA-sequencing datasets in 
prostate cancer must be generated to distinguish any recurrent allelic alterations. Currently one study of this 
nature has been conducted in prostate CTCs (158) and future investigations will hopefully encompass all 
situations of disease states. 
Inflammation of the Prostate – A Route to Cancer 
Evidence of an inflammatory aetiology for prostate cancer has been proposed for many years. (reviewed in 
166,167) Development of inflammation due to infection (prostatitis itself is the most common prostatic 
disorder) (186) stimulates the infiltration of immune cells. Secretion of chemo- and cytokines in this 
environment has the propensity to transform the stem cell population. Our lab has previously identified an 
inflammatory gene signature specific to prostate CSCs that includes active NF-kB, IL-6 and IFNGR1. (81) 
Elevated serum levels of the IL-6 cytokine are common among prostate cancer patients with late-stage disease 
and can be correlated with poor prognosis. (187–189) Induced IL-6 secretion by CSCs will therefore establish 
an autocrine signalling loop, as the CSCs constitutively express IL-6 receptors.  Activation of a downstream 
survival pathway reliant upon phospho-STAT3 evidently presents a selective advantage for the stem cell. (190) 
A comparable positive feedback loop incorporating NF-kB, IL-6 and STAT3 induced transformation in a breast 
epithelial cell line and simultaneously enriched for a CSC phenotype. (191) Similarly, STAT3 activation acts as a 
bypass pathway of androgen dependence, during chemical castration in prostate cancer (192) and in the 
maintenance of self-renewal pathways of glioblastoma CSCs. (193) Development of STAT3 phosphorylation 
(190,192,194) and DNA-binding inhibitors both mark promising alternative therapies for prostate cancer. (195) 
Whilst persistent infection triggers an exogenous supply of IL-6 from invading lymphocytes and/or 
macrophages to produce an initial inflammatory stimulus, IL-6 addition to the niche promotes an adaptive 
change in the stem cell which is then manifested into a positive feedback signal. Activation of a stem cell, by 
what is termed cytokine addiction, in this environment will grant a selective advantage in the new pro-
inflammatory nature of the niche. The raised systemic IL-6 concentration from non-tumour cells, including 
stroma,  in advanced prostate cancer patients may also provide an additional factor for successful 
expansion/survival of metastatic CSC clones.(187) Other CSCs have been observed to create feed forward 
favourable selection pressures; skin cancer progenitors establish a VEGF autocrine loop to support extrinsic 
vasculature and intrinsic self-renewal pathways.(196) This ultimately demonstrates the potential of prostate 
CSCs to modulate the niche micro-environment in response to inflammation. Given the convergence of many 
inflammatory signalling pathways via NF-kB, IL-6 may represent only one of many routes to stem cell 
transformation. (81,197,198) 
Stromal cells also contribute towards carcinogenesis and become reactive even during pre-malignancy (PIN). 
(129) Heterotypic signalling between the stroma and the epithelium is perturbed in disease (reviewed in 15) 
and the normal stromal cell phenotypic constitution alters; smooth muscle is replaced by cancer associated 
fibroblasts that are activated to myofibroblasts – a transition regularly observed at sites of wound healing and 
tissue remodelling. (199) Reactive stroma can promote the tumourigenesis of prostate epithelial cells in mice 
and in culture, highlighting the importance of reconstituting a favourable micro-environment in “successful” 
cancers. (11,200) Altered extracellular matrix ligand expression, such as higher levels of collagen 1, is also seen 
in disease and may aid constitution of the CSC niche. (53,129) TGF-β overexpression has been shown in vitro to 
induce reactive stroma, a molecular event that also begins in high-grade PIN tissues. (129,201) Stromal 
production of chemokines can produce synergistic effects alongside TGF-β signalling to enhance tumourigenic 
epithelial growth. (202) The same chemokines have also been linked to prostate cancer invasion, metastasis 
and immune cell infiltration of the primary tumour. (203) 
Elevated intra-tumoural presence of immune cells can, counterintuitively, aid progression of the cancer. (204) 
Indeed, T cell infiltrates are often quiescent or “exhausted”, as shown by the expression of canonical markers 
such as PD-1 and its cognate ligand. (205) These clusters also have high numbers of regulatory T cells 
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suggesting a negative effect is compounded upon wider T cell responses against the cancer. (205,206) The 
presence of tumour associated macrophages is linked to a heightened risk of biochemical recurrence, (207) 
whereas increased levels of natural killer cells are associated with lower chances of disease progression. (208) 
B cell numbers are also elevated in tumours, as identified by matched tissue analysis from prostatectomy 
samples. (209) The presence of these lymphocytes can activates stem-like transcription of Bmi-1 in cancer cells 
via non-canonical NF-kB signalling, to contribute towards self-renewal processes. (210) Tissue damage in the 
prostate, followed by the influx of immune cells, produces a reactive milieu of cytokines and growth factors, a 
cocktail that could potentially fuel the transformation of the epithelial stem cell niche as identified through 
inflammatory expression signatures in this rare cell population. (81,190) 
Aetiological Inducers of Prostate Cancer: Inflammation may also be linked to Dietary, 
Chemical and Infectious agents 
In an intriguing example of how environmental factors affect prostate tumourigenesis is the increased 
incidence of cancer in Japanese migrants to Hawaii, from extremely low to the level of the indigenous 
population. (211) The mere act of crossing the Pacific Ocean is certainly not attributable to this rise in 
incidence; a change in a habit, diet (212) or an endemic infection is much more likely. However, this data can 
also be interpreted as a racial predisposition of prostate cancer which is more intimately linked to 
environmental factors than previously thought. 
Epidemiological studies have connected an increase in prostate cancer incidence with the ingestion of red 
meat and animal fat; (213,214) a possible mechanism of carcinogenesis postulated to be through formation of 
heterocyclic amines (HCAs). (215) Dietary supplementation of one such HCA; 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) in rats induced formation of intestinal, breast and prostate carcinomas. 
(216) PhIP triggered an increased mutational frequency in the prostate and was found to have lobe-specific 
effects in the rodents which progressed through stages of epithelial atrophy, PIN and, finally, into cancer. 
(185,217,218) Recent research has found that dietary PhIP synergises with bacterial prostatitis and the IL-6 
cytokine in promoting prostate carcinogenesis. (219,220) 
Do Infectious Agents Induce Prostate Cancer? 
Infection of the prostate by pathogenic organisms also produces an inflammatory response. Most of these 
agents are sexually transmitted, including;   Neisseria gonorrhoeae,(221) Chlamydia trachomatis, Trichomonas 
vaginalis, Mycoplasma genitalium,(222) Treponema pallidum (syphilis),  Ureaplasma urealyticum,  Herpes 
Simplex Virus types 1 and 2, Human Herpes Virus 8, Human Papillomaviruses (HPV) (223) and Cytomegalovirus. 
(224) Recent meta-analysis of results accrued on sexually transmitted infections (STI) influencing prostate 
cancer concluded that men infected with gonorrhoea have a 20% increased risk of developing malignancy and 
a past history of any STI correlates with heightened incidence of cancer later in life. (225) 
Propionibacterium acnes, a bacterium primarily associated with acne, (226) is also recurrently found in 
prostate tissues with histological evidence of inflammation. (227,228) In vitro and in vivo studies utilising 
P.acnes have uncovered striking results. Co-culture of the bacterium with the RPWE-1 prostate epithelial cell 
line produced a complex immunological response with secretion of cytokines, including IL-6, and concomitant 
activation of NF-kB and STAT3 (229) -  a scenario resembling the inflammatory phenotype of prostate CSCs. 
(81,190) A mouse prostate model of P.acnes infection showed stimulation of epithelial neoplasia accompanied 
by inflammation and molecular changes including downregulation of NKX3.1 and AR. (230) 
HPV, more frequently associated with cervical carcinoma, has become increasingly linked to prostate cancer 
aetiology. Infection with the virus correlates with high Gleason grade and lower survival rates. (231,232) 
Conversely, other studies have found absence of HPV sequences in prostate tissues (233,234) suggesting that 
the presence of the virus may just be correlative, yet further studies are required to assess the involvement of 
the pathogen in disease. 
Epstein-Barr virus (EBV), previously implicated in both haematological and epithelial malignancies, has also 
been detected in prostate tissues.(235) It is thought that EBV may enhance HPV 18-mediated prostate 
oncogenesis.(236) Human BK polyomavirus has also been repeatedly identified in prostate cancer and its 
proposed precursor lesions. (237,238) BK T antigen is a protein that can nullify canonical p53 and Rb tumour 
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suppressor proteins, facilitating a non-mutagenic route of simultaneously abrogating gene function early in 
disease. (238) However, seropositivity to BK virus in prostate cancer patients has been linked to a reduced risk 
of biochemical recurrence, suggesting the virus is a positive prognostic factor although larger sample sizes are 
required to elucidate the role of the virus in disease development. (239) 
With the depth of next-generation sequencing technologies, it is now possible to detect low abundance DNA 
of bacterial and viral pathogens in whole prostate tissue, (240) although targeted PCRs have allowed previous, 
if limited, detection of novel-prostate inhabiting species.(241–243) It is entirely probable that an unknown 
species may play a pivotal role in prostate cancer yet their inability to be successfully cultured from patient 
tissue has abrogated identification of the pathogen.  
Further Evidence for an Inflammatory Aetiology of Prostate Cancer 
Other studies that suggest an inflammatory aetiology for prostate cancer, through infectious agents or a 
compromised immune system, are the findings that; immunosuppression in transplant patients increases the 
risk of subsequent prostate cancer development, (244) the frequent use of non-steroidal anti-inflammatories 
slightly lowers incidence of prostate cancer, (185,245–247) and that inflammation of surrounding benign 
prostate tissue is positively associated with higher Gleason grade cancers. (248) All could indicate either a 
divergent inflammatory initiating event or a persistent progression stimulus. 
Current evidence (249) suggests that inflammation and infection play a role in prostate carcinogenesis. Future 
studies, especially those involved in sequencing of large patient cohorts, should focus on identifying 
recurrently present infectious species with a further aim to distinguish molecular mechanisms of 
pathogenicity.  
Prostate Cancer Pre-malignancies 
Current carcinogenesis models argue strongly for the existence of an “activated” pre-malignant state, as 
previously discussed. The prostate is an organ in which pre-neoplastic disorders, including proliferative 
inflammatory atrophy (PIA) and PIN are relatively common. Tumours develop almost exclusively in the 
peripheral zone of the organ mimicking the zonal selectivity of hypothesised pre-malignancies; PIA and PIN. 
(185) Figure 5. 
Damage to the tissue by an initiating inflammatory insult leads to PIA; a focal regenerative hyper-proliferative 
response from the epithelia. PIA has been shown to merge with regions of PIN and cancerous tissues – 
providing further evidence for both a field effect of development and a step-wise disorder progression of 
carcinogenesis. (250,251) Most studies have shown that these atrophic regions do not harbour genetic defects 
(107) yet anti-apoptotic Bcl-2 and protective GSTP1 (251) are both upregulated whilst known prostate cancer 
tumour suppressor genes;  PTEN, NKX3.1 (252) and CDKN1B (253) are downregulated. This may represent a 
field of epigenetic activation prior to carcinogenesis.(254,255) These downregulated genes are also targets of 
heterozygous deletion in adenocarcinoma. (185) A recent study utilising an extensive amount of biopsies 
found a link between prostatitis and PIA yet not a transition between PIA and low grade PIN, (256) thus 
additional molecular and histological proof is required in support of this theory. 
Figure 5. Phenotypic, micro-environmental and molecular changes incurred through the pre-malignant states of prostate 
cancer. Processes describe ongoing changes during progression and molecular changes are characteristic of each individual 
stage and transitional change through pre-malignancy into cancer. 
There is probably stronger evidence for PIN as the major pre-cancerous lesion of the prostate.(257) This is 
characterised by enhanced luminal cell hyperplasia, and is biochemically, genetically and phenotypically similar 
to prostate cancer yet lacks any disruption of basement membrane.(10,107) The relative mitotic rates of the 
cells in the epithelial bilayer are reversed in PIN and the secretory cell population expands, foreshadowing the 
aberrant differentiation program of prostate cancer.(258) Numerous studies have reported coincidence of 
cancerous and PIN tissue, again supporting the FC theory. (259,260) The expressional profiles of PIN and 
prostate cancer have greater congruency between them than observed at any other defined stage in disease 
progression.(107) Additionally Tomlins et al. highlighted a reliance on ETS transcription factor driven gene-
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expression in PIN. A more recent study has identified that, in some cases, high-grade PIN (hgPIN) lesions are 
retrograde carcinomas that have invaded normal glands. By establishing clonality through utilisation of unique 
TMPRSS2-ERG breakpoints and tracking cancer lesions with adjacent hgPIN, sub-clonality of PTEN loss was 
then used to mark molecular progression in the cancer. The identification of PTEN deletion in the “hgPIN” 
showed that the histopathologically identified neoplasia was in fact cancerous.(261) This suggests that other 
studies stating adjacent PIN has cancer-initiating defects, including the TMPRSS2-ERG fusion, (262) SPOP 
mutation (263) and NKX3.1 loss, (258) may have in fact been sequencing cancer cells that, by pathology, mimic 
PIN. The conversion rate of hgPIN into prostate cancer has also been interrogated. One study repeated biopsy 
1 year following diagnosis of neoplasia and found that only ~13% of cases had “progressed” into cancer. This 
approach does have limitations, including the inaccuracy of core biopsies that may have missed cancer nodes 
upon PIN diagnosis and also the relatively short time frame between subsequent biopsies.(264) Whilst 
correlation of numerous molecular details is attractive the fact however remains that, currently, we have no 
absolute evidence of the progression of PIN into prostate cancer. 
Prostate Cancer; Incidence in Autopsies 
For more than 80 years, detection of prostate cancer at random autopsy has also yielded valuable information 
about the disease.(265,266) Striking observations from these studies, in which patient mortality wasn’t 
attributable to cancer, include; (i) the number of “latent” cancers found and (ii) prevalence of cancer directly 
proportional to the age of the subject. Detection of prostate cancer in men in their twenties has also been 
reported.(259) Globally, prostate cancer prevalence is roughly equivalent with variation in racial population 
incidence and mortality rates.(267) The extremely high discovery rate of cancers that had not progressed to a 
clinically detectable stage, suggests that prostate tumours may pass through a 15-20 year latency period, as 
implied by PSA testing of men in their early forties.(268,269) Whether this is universal for progression or is a 
feature unique to indolent prostate cancer remains unknown.(267,270) However if there is an extended time 
of latency in cancer, as suggested by modelling in the colon (34), then this pause could be attributable to the 
CSC hypothesis.  
Benign Prostatic Hyperplasia (BPH) 
Normal post-natal prostatic growth occurs during puberty, due to a rise in endogenous testosterone. The 
organ can also undergo abnormal enlargement later in life, for example due to due to BPH. The latter is a 
chronic disease that exclusively affects the transitional zone of the organ, and causes constriction of the 
descending urethra – resulting in urinary retention and discomfort.(271) However, this hyper-proliferative 
disorder doesn’t result in cancer. Our array data comparing states of cancer and BPH found that they are 
transcriptomically disparate (81) whilst also being phenotypically distinct in the fact that BPH can show 
hyperproliferation of the basal epithelial layer whereas cancer involves pronounced expansion of luminal 
cells.(272) In a recent publication detailing telomere dynamics through BPH, accounting for telomerase (TERT) 
activity, we have also shown the possible existence of divergent progenitors; one for the basal cells and the 
other for the luminal epithelia. (273) 
Telomeres and Telomerase; a clue for Aberrant Differentiation in Cancer 
Telomeres act as a buffering system to the end-replication problem in mammalian cells. Chromosome ends are 
reduced by 100-200bp after every cell division, thus telomeres shorten with age. Reductions in telomere 
length cause genomic instability and can result in chromosomal rearrangements.(274) Reactivation of 
telomerase in the presence of shortened telomeres, where tumour suppressor gene function has been 
compromised, is sufficient to generate multiple genetic rearrangements with the propensity to drive bone 
trophic metastases in a mouse model.(275) Telomere shortening is commonly seen in prostate cancer (276–
279) alongside a restoration of, or indeed, an increase in germline telomerase activity.(276,280) This 
presumably allows the cancer cell to acquire an element of genomic instability whilst maintaining sufficient 
telomeric repeats to avoid replicative cell senescence. (274,281) A recent study found that prostate cancer 
patients with increased intercellular heterogeneity among telomere lengths had a significantly greater chance 
of developing advanced lethal disease.(282) Interestingly, telomeres are also shortened in PIN with congruent 
activation of telomerase – giving a molecular correlate in this supposed pre-malignancy.(277,279) Normal 
prostate epithelia, including the stem cells, lack telomerase, yet levels of the enzyme increase during disease 
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onset and progression into castrate resistant prostate cancer (CRPC). The shortened telomere lengths inn 
cancer suggest a burst of expansion in the TERT
-
 stem cell pool during PIN, followed by maintenance of this 
length in TERT
+
 cancer cells.(283) The telomerase-positive signature is restricted to the aberrantly 
differentiated luminal cells of tumours, driving further clonal heterogeneity and maintaining viability whilst 
protecting against replicative senescence in this luminal cell pool.(284) 
These recent observations from our lab may explain the aberrant differentiation seen in tumours that lose 
basal cells and become dominated by the luminal cell phenotype. Figure 6. 
Basal cancer cells of the prostate do not express telomerase, thus experience replicative senescence and are 
removed from the tumour. The luminal cancer epithelia express active telomerase, allowing for maintenance 
of chromosome termini and cellular survival.  Hypothetically, shortened telomeres in the basal CSC increases 
genomic instability, to facilitate the chromoplexy seen throughout tumours and, as the prostate is a small, 
relatively slow cycling organ, these cells never encounter replicative senescence or have alternative telomere 
lengthening mechanisms.(283,285) 
The telomere lengths in fractionated BPH cells supports the existence of separate lineage progenitors for basal 
and luminal cell layers. The same may also be true in cancer, even though luminal cells can be derived from CB 
cells in normal prostate, (5) yet if the basal lineage becomes a “dead-end”, the shifting of asymmetric divisions 
to produce the luminal progenitor may become favoured from the CSC. (273) 
Figure 6. Telomerase in Prostate Cancer Development    
The TERT
- 
stem cell pool expands during PIN which shortens the telomeres. Progression into cancer occurs and telomerase 
activation in the luminal epithelial cells allows for maintenance of the shortened telomeres and prevention of replicative 
senescence in this mitotic cell population. Conversely the lack of telomerase in the basal cells of the prostate means that 
telomeres will continue to shorten. The lineage enters replicative senescence and would be lost from acini. 
The role of this aberrant differentiation is still unclear, but as AR is the most potent neoplastic effector in the 
prostate, utilising this molecule in the dominant luminal cell type is advantageous for the cancer to increase in 
size and develop hetero-clonality. 
Driver and Passenger Mutations in Carcinogenesis 
Mutation is the most obvious and traditional route into, firstly, transformation of a normal cell and, secondly, 
the creation of intra-tumoural heterogeneity. With the advent of next generation sequencing, mapping the 
mutational landscapes of cancer has allowed identification of recurrently altered pathways and genes amongst 
different cancer types. (286,287) Driver mutations are defined as those that confer a proliferative advantage to 
the recipient cell – these are centred about 12 pathways encompassing cell cycle regulation, survival etc. and 
currently ~140 genes have been described as drivers in cancer.(22) It would be expected that such changes 
begin in cancer-initiating normal cells as part of pre-tumour and pre-malignant progression. Sequencing 
studies however pick up far more mutations in tumours than is necessary to transform a cell. These 
background changes are termed passenger mutations; they themselves do not grant the cell any micro-
evolutionary benefit but are merely interred in the cells that have been selected through advantageous driver 
mutations and are “along for the ride”.(22) However such changes may become adaptive, and produce a 
favourable outcome in response to a selection pressure such as treatment, but otherwise would confer no 
advantage in the present micro-environment. Figure 7. Aberrant epigenetic events can also act as drivers. 
These permit mutagenic changes yet afford plasticity, allowing response to variant selection pressures such as 
micro-environmental alteration or treatment.(22) There is also evidence of, in pre-tumour development, 
epigenetic progenitors of cancer in which the initial tumourigenic changes aren’t fixed mutations, but subtle 
changes in the expression levels of genes.(reviewed in 248) Analysis of late-stage tumours is thus a process 
with almost irreconcilable complexity, given the number of mutations. The key question when presented with 
the vast number of mutations present in cancers is; which drive the cancer and which are passively present?  
 
Figure 7. Driver mutations in Cancer 
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A. In a field of cells, two have acquired an identical driver mutation (red bolt) that confers a proliferative advantage 
over the non-affected cells. 
B. A cell in then accrues a secondary mutation (yellow bolt) that confers no advantage in the current micro-
environment and the cell populations’ proliferative indices remain the same. 
C. A micro-environmental change occurs, for example inflammatory stimuli or cancer treatment. 
D. In this new microenvironment, the previously passive mutation (yellow bolt) now confers a selective advantage 
over cells that have just the original driver mutation, demonstrating the appearance of adaptive mutations in 
cancer. 
The theory of step-wise carcinogenesis is much like the clonal evolution model, in that it implies an initiating 
driver event which affords the originating cell the opportunity to form a neoplastic clonal field. Cells in this 
field can then undergo further selective mutations resulting in generation of a clonally diverse pre-malignancy 
and, providing the eventual acquisition of a minimal number of driver events, the first cancerous cell clone. 
The original linear step model proposed by Fearon & Vogelstein (20) however places metastatic potential as a 
final acquisition by cancer cells as the disease trends towards patient death. More recent evidence (288) 
suggests that metastasis may in fact occur much earlier in progression than initially thought, but remains 
undetectable due to the inefficiency of the process, development of required adaptive phenotypic changes for 
secondary site seeding and latency of micro-metastases. (116,289) This early EMT may in fact be stimulated by 
immune cell invasion of the primary tumour, (290) an event that occurs recurrently in prostate cancers. 
Another criticism of a linear route is that if mutations were to occur sequentially in cells, without concurrent 
dysregulation of apoptosis, then surely the cell would be deleted by still-functional “quality control” 
mechanisms. The accumulation of driver mutations in pre-tumoural development (34) would of course be 
separated temporally yet may not be presented by the affected stem cells until there was subsequent or 
indeed previous removal of signalling pathways that may result in cancer cell death. For illustrative purposes, 
HPV oncogenesis mediated by E7 and E6 proteins requires the presence of both proteins to escape cell 
deletion; E7 binding to Rb causes cell cycle dysregulation but needs E6 to inactivate p53 to prevent deletion of 
aberrant replicating cells. (291–293) However, most p53 mutations are regularly observed in CRPC only after 
treatment (294) and are uncommon in early disease.(295,296) Deep sequencing may soon be able to address 
this problem by detecting the presence of “final” mutations in minute cellular populations of early-stage 
cancers, but the current limit of such studies (0.02%) may be insufficient in detecting rare clones.(297) A  
The definitive number of driver events that can separate normal and cancer do however seem to be tissue-
specific. Early studies estimated that there needed to be 6-7 of these mutations to transform a cell (298) but 
current mutational modelling suggests a lower number of 3 key mutations in most solid tumours.(287)  
Leukaemias, on the other hand, may require only a single event such as the RUNX1-ETV5 or BCR-ABL fusions, 
providing a reasonable explanation for the childhood onset of blood cancers.(18,299) Sequential mutagenesis 
in prostate cancer mouse models has shown that between one and three specific mutations are required for 
carcinogenesis.(10) 
Genetic and Epigenetic Aberrancy in Prostate Cancer 
Prostate tumours differ from the vast majority of solid tumours in that they favour copy number variations to 
orchestrate cellular dysregulation, rather than targeted point mutations.(27,149,184,263,300,301) This 
“scrambling” of the prostate cancer genome occurs in a patterned and coordinated manner of chained events 
referred to as chromoplexy. The temporal frame of these linked deletions and translocations is unknown, but 
probably accumulate over a prolonged period, due to observed clonality of founder events (TMPRSS2-ERG 
fusion and NKX3.1 deletion) and sub-clonality of “later” alterations (PTEN and CDKN1B deletions). Deletions in 
the classic tumour suppressors, RB1 and TP53 are also observed, albeit in more advanced cancers.(184) 
Presumably prostate tumours’ aberrant DNA repair mechanisms facilitate chromoplectic reorganisation of the 
genome and these changes also present in the CSC.(81,82) 
Sequencing has also identified an enrichment of events that dysregulate chromatin modifying enzymes in 
prostate tumours. The H3K27 methyltransferase EZH2 is upregulated and its locus frequently amplified in 
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advanced cancers.(107,149) EZH2 expression can be activated by ERG and has been shown to influence a de-
differentiation program,(302) by transcriptional silencing of critical genes, for example NKX3.1.(303) Recurrent 
mutation of MLL2, another H3 methyltransferase (Lysine 4), that interacts with and facilitates epigenetic 
transactivation of AR, has also been observed.(301) Interestingly these enzymes are involved in maintenance 
of bivalent chromatin,(176) where dual histone methylations mark a gene-set that becomes dysregulated in 
prostate cancer development.(154) Multiple methyltransferases and demethylases are also abrogated in 
disease, with alteration presumably compounding dysregulating effects on the transcription of target genes. 
(304–308) Specific epigenetic events certainly play a role in prostate tumourigenesis, however the extent to 
which the epigenome of prostate cancer is altered throughout disease development is only just being 
uncovered. (154,309,310) 
Recent studies have also allowed the identification of distinct molecular subtypes of prostate cancer. (184,301) 
This implies variant genetic founder events (Table 2) and may in future be aligned to stratify different 
treatment programs. The ETS factor status of the tumour can provide one classification paradigm. The 
TMPRSS2-ERG fusion was identified as a recurrent event in prostate tumours just over a decade ago (311) and 
is an established early event in around half of all prostate cancers.(149,184) Presence of the fusion is also 
detected in putative tumour initiating cells of the prostate.(81,82) TMPRSS2-ERG positive tumours also have 
recurrent deletion of loci including; PTEN, TP53 and 3p14 – a region containing three proposed tumour 
suppressing genes.(149,184,263) Deletion of CHD1, a chromatin remodelling protein, in addition to SPOP 
mutation, are mutually exclusive of the fusion, suggesting a variant initiating event. CHD1 is thought to be 
involved in the production of the TMPRSS2-ERG fusion by its co-recruitment to androgen responsive 
promoters, thus loss of CHD1 abolishes the possibility of generating a fusion and creates a variant lineage of 
prostate cancer. (312,313) Although genetically disparate, fusion positive and SPOP mutated tumour classes 
exhibit biological convergence as both increase ERG protein expression (314,315) and display genomic 
instability.(149,316)  Transcriptomics and genomics have allowed for further assimilation of comprehensive 
mutational and expression signatures that can be used to stratify prostate tumours. (149,317–319) 
 
Table 2 – Molecular defects which can drive primary prostate cancer 
These sequencing studies however fall short on two accounts; until recently they predominantly have used 
end-stage tumours but more importantly they all fail to sufficiently account for intra-tumoural heterogeneity. 
Figure 8. 
Most studies involve sequencing of advanced tumours, partially due to harvesting of tissue at autopsy but 
more effort to collect a wider range of samples of radical prostatectomies must be made to ensure that 
prostate cancer is mapped throughout each stage of disease. This would inform on the development of 
tumours at various prognostic levels and give us an extrapolated view to pin down true initiating events. 
Figure 8. Understanding Heterogeneity – a tumour model to illustrate the difficulties of disseminating cellular diversity in 
prostate cancer 
Prostate cancer is regularly multi-focal. These separate tumours are not identical and often have variant founder events 
and characteristic mutations. DNA/RNA sequencing of sections taken from different positions A-D of the prostate in the top 
left of the illustration will produce differing combinations and percentages of focal tumour tissue. This will give an averaged 
mutational signature between the foci (1, 2 and 3) and, without cellular fractionation, will not be able to distinguish 
between epithelial and stromal cell type profiles. 
Heterogeneity of mutational foci can also exist within the tumour epithelium due to sustained sub-clonal expansion from 
different CSCs.  Clonal mutations would also accumulate through cellular division along the acini (x -> y -> z). Branching of 
acini can show divergence of the parental tumour cell populations with a shared founder event, and the creation of sub-
clonal pools with different mutations (slice E). The lower image (E) is a transverse section across the 2 divergent acini in slice 
E in the upper right representation of the tissue.  
By combining sequencing, immunohistochemistry with the separation of cellular populations, identification of the cell type 
in which mutation originated and tracking of said mutation through the lineage hierarchy in multi-focal prostate cancer will 
be possible. 
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Tumours are innately heterogeneous, composed of varying cancer cell types, cancer-associated cells and 
infiltrating immune cells. Processing an entire prostate tumour as a homogeneous entity allows no distinction 
between stroma, epithelia and the skewed epithelial populations. Ultimately the cells driving the cancer may 
be masked by bulk tumour cells. Multi-region sequencing of the primary tumour and metastases has provided 
some insights into the spatial and temporal evolution of cancers,(320,321) including that of the prostate. (322) 
Further improvements are required such as cell fractionation prior to sequencing efforts, and/or sufficiently 
deep coverage should in future be able to resolve the nature and origin of human prostate cancer 
heterogeneity. (323) 
The Role of Androgens in Prostate Cancer Initiation 
Neonatal morphogenesis of the prostate is directed by androgens, (324) as is growth of the organ during 
puberty, in what is thought to be an “imprinted” proliferative response.(325) Most cells of the prostate apart 
notably from stem cells express detectable levels of AR protein, however only the luminal cells depend upon 
the hormone for survival.(79) Expansion of the luminal cell monolayer in PIN and cancer strongly implies that 
AR is important in disease development. Indeed chemical castration by ablation of the androgen axis 
effectively de-bulks tumours, a realisation made over 70 years ago.(326) 
Androgens have also been shown to induce de novo TMPRSS2-ERG fusions in LNCaP cells through interphase 
co-localisation of both loci (dictated by AR transcriptional activation) twinned with topoisomerase II 
recruitment.(327–329) The creation of the fusion is a gateway event for establishment of an inappropriate ERG 
profile towards a de-differentiated state and androgen independence of cancer cells.(302,330) 
Aberrations of the AR gene itself are observed post treatment through locus amplification, (331) mutation 
(332) and aberrant splicing. (333) These events drive activation of the receptor in castrate levels of androgen. 
Prostate cancer also hosts frequent mutational and expressional changes of AR regulatory proteins including 
SPOP, (263,334) NCOA2, (149) FOXA1, (263) MLL2 (301) and RNF6.(335) This highlights the importance of 
androgen signalling for the fate of luminal cancer cells of the prostate. The dominant disease “signature” 
identified by these studies could also be due to the skewing of the prostate epithelial lineage in 
tumourigenesis, and it is therefore unsurprising that prostate cancer has perturbations in this neoplastic 
pathway. 
Androgen ablation, is initially successful and causes involution of the normal prostate and a reduction in 
tumour mass yet, it almost inevitably fails at longer term. Relapse of CRPC occurs in almost every patient. AR 
changes through mutation and amplification in small sub-clones undoubtedly exist in the tumour prior to 
treatment for the changes to be so common after relapse, but these alterations are rarely selected for in 
hormone naïve cancers. (294) 
Prostate CSCs express little or no AR protein and are independent of the androgen axis for survival, making the 
population a primary candidate for driving cancer relapse.(79,336) The castrate levels of androgen may select 
for AR
+ 
TA cells that have AR alterations, to kick-start tumour regrowth.  
DNA Damage Repair and Response Defects  
Genome instability is regarded as a hallmark of cancer as it allows for acceleration in the mutation rate that 
can either predispose or accelerate existing cancer development. Telomere shortening, defects in response 
and repair of DNA damage all contribute to instability and offer a worsened prognosis in prostate cancer. 
(282,337) 
Similar to other malignancies, prostate cancer often presents with compromised DNA damage response 
pathways, (319,338) however tumours with true mutator phenotypes only ever present after treatment. 
(323,339) Population and familial studies have shown that a number of genes predispose for prostate cancer.  
Mutation of BRCA1 and 2, commonly related to ovarian and breast cancers in women, increases the risk of 
development of prostate cancer in men.(340,341) Chk2 mutations were also shown to be elevated in families 
with hereditary prostate cancer.(342) Numerous population studies examining the risk factors of single 
nucleotide polymorphisms in DNA repair genes found several allelic variants for genes such as PARP1, XRCC1 
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and ATM.(343) Defects in this quality control system are also observed in sporadic tumours with mutation of 
ATM and p53 in advanced disease.(344) 
Oncogene-mediated replicative stress through AKT (ungated activation due to common PTEN loss (345)) and 
Myc further destabilise the genome.(346) AKT enhances non-homologous end joining (NHEJ) that, in the 
setting of prostate cancer, presumably serves to create mutagenic rearrangements.(184,338) AR is dependent 
on PARP1 for general transcription (347) and the nuclear receptor also responds to DNA damage by facilitating 
expression of XRCC2 and XRCC3 that function in homologous recombination repair alongside upregulation of 
DNA-PKCS, a key NHEJ enzyme. (348) 
Prostate tumours with mutator phenotypes have been identified and attributed to MSH2 and MSH6 mismatch 
repair enzyme mutation and rearrangements.(149,263,323,339) Whilst these defects present more frequently 
in advanced cancers, there is evidence that disruption of these enzymes is also present in primary 
tumours.(339) However the mutation may be a more recent event in establishing metastatic clones, rather 
than driving early disease. 
Variants of DNA repair genes have also been shown to promote the formation of the TMPRSS2-ERG fusion. 
These genes were identified through linkage studies in ETS
+
 tumours and included BRCA2, ESCO1 and POLI. 
(349) Interestingly it was also shown that inducing genotoxic stress promotes fusion formation in a prostate 
cell specific manner, (328) due to transcriptional proximity of AR induced loci. 
Conclusion – Current Evidence and Future Work 
There are still no definitive epigenetic or genetic events that initiate prostate cancer. However it is clear that 
inflammation is involved in the development of putative precursor lesions, and carcinogenesis of the prostate. 
This observation holds true for many other cancers, including stomach and colorectal carcinomas. Increasing 
evidence that environmental factors can also overcome the supposed racial component of disease is also 
intriguing. There may be a culprit hiding in plain sight to account for the huge discrepancy of the disease 
incidence between men in well-developed and undeveloped regions in the world, aside from longevity and 
causes of premature death. Cancer found recurrently at non-related autopsy also suggests that prostate 
tumour development may be a case of when and not if. 
Cellular Origins of Human Prostate Cancer; Summary and Further Work 
Combination of CSC and stochastic/clonal models of disease is possible in prostate. The frequency of diagnosis 
of disease in older men, and the slow relapse of CRPC suggests a transformational event in the stem cells. Yet 
the aggressiveness of late-stage disease, reliance of CRPC on perturbed AR pathways and the sequential 
adaptive mutation seen in metastatic lesions suggests the runaway nature of dominant clone/s. 
If we view primary tumours as dysregulated tissues, a hierarchical ordering of cells is necessary, but perturbed 
in cancer.(31) Tumour cells often show greater plasticity than normal counterparts, and the initiating stem-like 
cells prove the most flexible in their phenotype and in some cases are capable of trans-differentiation.(51) 
There is clear evidence of a CSC pool in the human prostate (32,83,139,350), however one unknown is 
whether this is a fixed population or whether it is maintained through constant plastic transitions into and 
from more differentiated “progeny” which really becomes an issue upon targeted treatments of CSCs. Here 
the adaptive nature of the CSCs may render them “untouchable” to targeted treatment, as they could 
fluctuate between cell-types.(351) There is also the observation that founder mutations such as the TMPRRS2-
ERG fusion, although found in the CSC, are more easily formed in androgen responsive cells. Is it the mutation 
that allows for de-differentiation or is it accrued in a phenotypically fluctuating CSC? (302,327–330) 
Further work also needs to be undertaken to dissect inter-CSC heterogeneity in the prostate. This will require 
discovery and utilisation of markers exclusive to separate CSC populations. Identification through deep-
sequencing of fractionated CSCs will be the obvious route to this goal and will ideally identify metastatic and 
dormant sub-populations of progenitors. Markers can then be utilised in selective searches of CTCs and to 
validate CSC seeding of metastatic disease. Segregation of CSC populations on tissue Gleason grade (preferably 
from the same cancer which will prove a challenge) may also shed light on clonal or transitional progression of 
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prostate cancer in indolent and aggressive disease. Even current single-cell sequencing from tumours and 
blood circulation reveals an array of genotypes and phenotypes in a single patient. (158,162,164,352) 
Building up a profile of prostate CSCs through Genome, RNA and ChIP sequencing will cut through the 
heterogeneity of prostate cancer and allow relevant genomic, transcriptomic and epigenetic data to be 
discerned without the CSCs being masked by overlying basal and luminal cell signatures. Single-cell data is also 
required and will yield information on 2 fronts; the assessment of chromoplexy to a greater detail with 
confirmation whether these catastrophic genome rearrangements are tolerated by the CSC, and the presence 
of bivalent genes in the CSC followed by monoallelic expression analysis in more differentiated progeny as an 
assessment of both expressional heterogeneity and contribution of the phenomenon to disease. 
Generation of the same profiles for the more differentiated cells of the prostate will be key to identify variants 
that can be used in targeted therapies, and accrual of this data in temporally and clinically separated stages of 
disease will inform on progression and possible routes to block the advancement of prostate cancer. 
Dissemination of this heterogeneity will be especially useful in early stage primary tumours, where the 
genomic data is extremely convoluted, due to uncertainty of driving and passive events alongside dominant 
cell type “artefacts”.  
Defining Prostate Cancer Pre-malignancies 
PIA and PIN are, in the light of current evidence, genuine precursor lesions of prostate cancer. However 
definitive proof rather than transcriptomic congruence and histological adjacency is still required. Cytochrome 
oxidase deficiency has been used previously for stem cell lineage tracking in the prostate (7) and could be used 
in a similar manner to track clonality through PIA, PIN and into cancer. This experiment would require cross 
sectioning of prostate tissue that has adjacency of PIA, PIN and cancer through acini. Our methods in tracking 
telomerase activity and telomere length in BPH and cancer may also be of use here. (273,283) 
Inflammation; importance and modelling of disease 
To address the inflammatory nature of prostatic disorders and the contribution that this environment makes 
towards carcinogenesis, whole tissue sequencing studies should attempt to incorporate open searches for 
pathogenic organisms in addition to the primary study goal. This will allow functional correlates to be 
discerned between disease stage and presence of potentially oncogenic bacteria and viruses. The infiltration of 
immune cells in the prostate could also be interrogated by these studies by taking blocks of tissue aside from 
sequencing efforts. This will allow a web of pathogen-immune system interplay to be constructed which may 
be used clinically to infer invasive species or indeed appropriate and inappropriate lymphocytic responses in 
the prostate. The cytokine environment of prostate cancer is evidently an important factor in disease; 
recurrent finding of IL-6, and concomitant STAT3 phosphorylation, as a synergic driver of transformational 
events (190,191,205) makes the point that other important inflammatory molecules are very probably 
included in a melee of micro-environmental triggers contributing toward tumourigenesis.  
The inflammatory noise of the in vivo environment is not re-encapsulated by current in vitro models. That and 
the lack of stromal co-culture marks a failure in disease which already has a shortage of cell lines. More effort 
is required to ensure that our mimics of prostate cancer are as close as feasibly possible to human tumours, in 
line with the adage; “All models are wrong, but some are more useful.” The lack of primary tumour and CRPC 
specific mutations in cell lines is also a problem. Currently only VCaP cells (353) harbour the TMPRSS2-ERG 
fusion and, until last year, no cell line contained an SPOP mutation or CHD1 deletion.  The work by Gao et al in 
the generation of seven CRPC cell lines is an extremely valuable contribution to the field and will bring readily 
usable and relevant models to enhance understanding of end-stage disease. (354) 
Castrate Resistant Prostate Cancer – a Cancer Stem Cell driven disease? 
The inevitable development of fatal CRPC is very probably induced by current treatment strategies. The 
ablation of androgen-dependent luminal cells (326) and selection of basal and neuroendocrine lineages 
(28,79,355–357) alongside sub-clonal mutated populations (332,358–364) suggest that androgen deprivation 
therapy may actually be enhancing disease aggressiveness and disrupting cellular genotypes.(365) For example 
genomic instability, a hallmark of cancer, is rare in prostate cancer yet appears post-treatment in the form of 
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tumours with characteristic mutator phenotypes.(323,339) Perturbed AR signalling is important in this stage of 
prostate cancer (354,366,367) and does have the ability to drive metastatic clones (158,368,369) – indicated 
by presence of locus amplification (331,370) and splice variants (333,371–375) in these cells. Androgen 
signalling however isn’t disrupted in development of the disease, where dysregulated ETS factors are more 
involved in progression.(107,184,301,314,315) 65% of CRPCs have detectable aberrations in androgen 
signalling, (294) but what is driving the cancers in the remaining 35%? This also doesn’t account for intra-
tumoural heterogeneity– some cells in the AR perturbed tumours won’t be necessarily driven by AR 
aberration.(376) The current focus on the state of the AR in CRPC while, although important, perhaps masks 
other recurrently altered molecular targets that could be exploited, such as PI3K and Wnt signalling. 
(158,294,377,378) Selective luminal cell searching in CTC and metastatic cell studies completely excludes the 
possibility that other prostate cell types contribute to disease and biases any results – also what could these 
studies be missing through their selectivity? In this respect there may be a case for hypothesis driving results in 
CRPC, whilst any evidence against anti-androgen efficacy or dependence of cells on androgen is ignored.  
Finally the presence of progenitor cells in metastases is yet to be determined in prostate cancer, although the 
possibility has been discussed.(379,380) Since prostate CSCs have enhanced invasive potential over metastatic 
cell lines,(32) express markers of EMT,(81) are androgen independent,(79) and  the messenger and micro-RNA 
signatures of CRPC resembles that of the stem cells (381,382) suggests an involvement the in metastatic 
spread of prostate cancer. Could these cells be drivers of minimal residual disease and castrate resistance? 
Disseminating the heterogeneity of the CSC pool will determine possible existence of a metastatic sub-clone 
that can be detected in both the primary and secondary seeded cancers – inference of metastatic tissue 
tropism may also be attainable from this data. Metastatic spread, although initially thought to be a late event, 
(20) is now presumed to occur early in cancer development and lie periodically dormant as micro-metastases. 
Accumulating knowledge on and the targeting of these metastatic clones is therefore paramount in prostate 
cancer.  
Concluding Remark 
It is perhaps not sufficient to conclude that prostate cancer has a multifactorial aetiology and is characterised 
by genomic and phenotypic heterogeneity. In short, each man’s cancer is somehow unique and attempts to 
characterise and design best fit treatments are naïve. Truly personalised medicine, based on understanding of 
the molecular and cellular characteristics, however heterogeneous, will provide the ultimate treatments.  
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  Table 1 –immunophenotypes of Human Cancer Stem Cells 
 
Tissue Immunophenotype Ref 
Acute Myeloid Leukaemia CD34
+ 
CD38
- 
(Bonnet & Dick 1997)(64) 
Bladder 67LR
+
 CEACAM6
+
 CK17
+
 (He 2009)(65) 
Brain CD133
+
 (Singh 2003)(66) 
Breast CD44
+
 CD24
-/lo
 (Al-Hajj 2003)(67) 
Colon CD133
+
 (Ricci-Vitiani 2007)(68) 
Cervix CD44
+
 CK17
+
 (Feng 2009)(69) 
Endometrium CD133
+
 (Rutella 2009)(70) 
Head and Neck CD44
+
 BMI1
+ 
(Prince 2007)(71) 
Liver CD133
+
 (Ma 2007)(72) 
Lung CD133
+
 (Eramo 2008)(73) 
Melanoma CD20
+ 
(Fang 2005)(74) 
Multiple Myeloma CD138
- 
(Matsui 2004)(75) 
Pancreas CD44
+
 CD24
+
 ESA
+ 
(Li 2007)(76) 
Prostate CD44
+
 α2β1
hi
 integrin CD133
+
 (Collins 2005)(32) 
Ovary CD44
+
 CD117
+ 
(Zhang 2008)(77) 
 
 
Table 2 – Molecular defects which can drive primary prostate cancer 
Primary Prostate Cancer Molecular Defects 
Oncogenic Drivers Tumour Suppressors 
TMPRSS2-ETS fusions 
A translocation or interstitial deletion event 
places an ETS factor, most commonly ERG 
but also ETV1, ETV4 and ETV5, under the 
control of the TMPRSS2 promoter. The ETS 
proteins are developmental transcription 
factors that affect proliferation, migration 
and transformation of cells. These gene 
fusions are seen in over half of all prostate 
cancers. 
PTEN deletion 
Heterozygous deletion of the PTEN gene is 
observed in ~40% of primary tumours. This 
causes haploinsufficiency of the gene product; 
PTEN is the reciprocal phosphatase of PI3K. 
Reduced removal of PI3K phosphorylations 
causes unchecked AKT activation that allows for 
increased cell survival and proliferation. 
Mutation of the gene is also observed. 
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MYC overexpression 
MYC is seen to be upregulated in early 
prostate tumours and its locus is frequently 
amplified in advanced cancers. The gene 
encodes a transcription factor that has well 
characterised transformative properties due 
to its role in cell cycle progression. 
CDKN1B deletion 
CDKN1B is deleted in ~20% of primary tumours. 
The protein acts is a CDK inhibitor that controls 
the G
1
 cell cycle checkpoint, loss of the protein 
allows for easier commitment to the cell cycle 
and thus promotes increased proliferation. 
Mutation of the gene is also observed. 
Telomerase activation 
The protection of chromosome ends by 
inappropriate activation of telomerase 
prevents replicative senescence in highly 
proliferative cancer cells. Telomerase 
expression is switched occurs during hgPIN 
and early prostate cancer. 
NKX3.1 deletion 
NKX3.1 is heterozygously deleted in up to 85% 
of prostate cancers and is downregulated in 
PIN. The protein is a homeobox transcription 
factor that regulates prostate epithelial 
development. 
IL-6 addiction 
Inflammation causes upregulation of both IL-
6R and oncostatin M, an IL-6 signal 
transducer, in the prostate stem cell 
population. An increase of systemic IL-6 in 
prostate cancer patients creates a positive 
feedback loop favourable towards 
transformation through enhanced STAT3 
activation and associated downstream gene 
expression. 
SPOP mutation 
SPOP is mutated in 6-15% of primary cancers. 
This is a molecular event that is mutually 
exclusive of TMPRSS2-ERG fusions. SPOP is an 
adaptor protein for the Cullin3 E3 Ubiquitin 
Ligase and directs the proteasomal degradation 
of oncogenic proteins such as AR, DEK and ERG, 
and is also involved in the DNA damage 
response and cellular senescence. Mutations 
cluster in the substrate binding domain of the 
protein and abrogate SPOP effectiveness. 
 CHD1 deletion 
CHD1 is commonly deleted in primary tumours, 
correlates with SPOP mutation and is thus 
mutually exclusive from the TMPRSS2-ERG 
fusion. The protein is involved in chromatin 
remodelling. 
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